Novartis AG ADR (NVS)vsInsulet Corporation (PODD)
NVS
Novartis AG ADR
$156.86
-0.50%
HEALTHCARE · Cap: $286.29B
PODD
Insulet Corporation
$148.93
-0.60%
HEALTHCARE · Cap: $9.79B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1757% more annual revenue ($56.69B vs $3.05B). NVS leads profitability with a 22.5% profit margin vs 12.3%. PODD appears more attractively valued with a PEG of 3.31. PODD earns a higher WallStSmart Score of 65/100 (C+).
NVS
Buy51
out of 100
Grade: C-
PODD
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.2%
Fair Value
$93.84
Current Price
$156.86
$63.02 premium
Intrinsic value data unavailable for PODD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Earnings expanding 328.6% YoY
Every $100 of equity generates 23 in profit
Revenue surging 23.5% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Moderate valuation
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : PODD
The strongest argument for PODD centers on EPS Growth, Return on Equity, Revenue Growth. Revenue growth of 23.5% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PODD
The primary concerns for PODD are P/E Ratio, PEG Ratio.
Key Dynamics to Monitor
NVS profiles as a value stock while PODD is a growth play — different risk/reward profiles.
PODD carries more volatility with a beta of 1.10 — expect wider price swings.
PODD is growing revenue faster at 23.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
PODD scores higher overall (65/100 vs 51/100) and 23.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Insulet Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?